Carboplatin (USAN:USP:INN:BAN:JAN)
41575-94-4N.N.O=C([O-])C1(C(=O)[O-])CCC1.[Pt+4]BHKICZDKIIDMNR-UHFFFAOYSA-L41575-94-4Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H302+H312+H332 (48.8%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
P203, P233, P260, P261, P263, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P321, P330, P333+P317, P337+P317, P342+P316, P362+P364, P403, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 82 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
BeschreibungCarboplatin is a second generation, platinum-containing antineoplastic agent with significantly reduced nephro-, neuro-, and ototoxicity in comparison to cisplatin. It is effective in the treatment of advanced ovarian carcinoma of epithelial origin and small cell carcinoma of the lung.
VerwendenData on carboplatin production have not been found. Carboplatin is used in chemotherapy to treat cancer, and more particularly to treat cancer of ovary, embryonal carcinoma of the testis, microcellular carcinoma of the lung, neuroblastoma, and squamous cell carcinomas of the head and neck.
Wird geladen…
Wird geladen…
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…